TScan Q2 net loss $31.7M; revenue falls to $0.5M; RMAT designation for lead candidates

TScan Therapeutics, Inc.

2024-Q2 EPS reported -$0.59 revenue$1,102,000

Revenue $0.5M, down from $3.1M in Q2 2023, primarily due to Amgen collaboration timing.
Net loss $31.7M vs $24.0M in Q2 2023; R&D expenses increased to $26.9M from $21.2M.
Cash, equivalents, and marketable securities $297.7M (plus $5M restricted); funds into Q4 2026.
FDA granted RMAT designation for TSC-100 and TSC-101 for AML, ALL, MDS post-HCT.
On track to report one-year heme data and initial solid tumor data by end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.